GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- COPD: Tailor therapy to individual characteristics
Risk of exacerbation correlates with the eosinophil count and other factors
- Focus on new therapeutic targets and senolytics
Cellular senescence
- Development of a quintuple agonist
New strategy in the fight against obesity and T2D
- From symptom to diagnosis
Oncocytoma
- Arterial elasticity, vascular ageing, endothelial function
Longevity and cardiovascular health 2025
- AI-supported risk stratification for chest pain in the emergency room
Performance of a fully automated ECG model
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Hormone balance and longevity